Ocular Therapeutix (OCUL) Receivables (2013 - 2026)
Ocular Therapeutix's quarterly Receivables came in at $24.3 million in Q1 2026, down 3.47% year-on-year from $25.2 million in Q1 2025, and down 20.56% quarter-over-quarter from $30.6 million in Q4 2025.
Ocular Therapeutix has reported Receivables for 14 years, with the latest figure at $24.3 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables fell 3.47% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 3.47% YoY), and the FY2025 full-year result was $30.6 million, down 5.37% from the prior year.
- Receivables for Q1 2026 stood at $24.3 million, down from $30.6 million in the prior quarter.
- The five-year high for Receivables was $32.4 million in Q4 2024, with the low at $19.8 million in Q3 2022.
- Average Receivables over 5 years is $26.1 million, with a median of $26.2 million recorded in 2023.
- Year-over-year, Receivables jumped 70.25% in 2022 and dropped 8.98% in 2023.
- Tracing OCUL's Receivables over 5 years: stood at $21.3 million in 2022, then advanced by 22.76% to $26.2 million in 2023, then increased by 23.72% to $32.4 million in 2024, then dropped by 5.37% to $30.6 million in 2025, then retreated by 20.56% to $24.3 million in 2026.
- The last three Receivables figures came in at $24.3 million (Q1 2026), $30.6 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 24.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.35 Mn |
| Dec 31, 2025 | 30.65 Mn |
| Sep 30, 2025 | 30.77 Mn |
| Jun 30, 2025 | 30.41 Mn |
| Mar 31, 2025 | 25.22 Mn |
| Dec 31, 2024 | 32.39 Mn |
| Sep 30, 2024 | 30.24 Mn |
| Jun 30, 2024 | 30.23 Mn |
| Mar 31, 2024 | 26.55 Mn |
| Dec 31, 2023 | 26.18 Mn |
| Sep 30, 2023 | 23.59 Mn |
| Jun 30, 2023 | 27.31 Mn |
| Mar 31, 2023 | 21.12 Mn |
| Dec 31, 2022 | 21.33 Mn |
| Sep 30, 2022 | 19.80 Mn |
| Jun 30, 2022 | 20.48 Mn |
| Mar 31, 2022 | 23.21 Mn |
| Dec 31, 2021 | 21.14 Mn |
| Sep 30, 2021 | 19.55 Mn |
| Jun 30, 2021 | 18.73 Mn |
| Mar 31, 2021 | 13.63 Mn |
| Dec 31, 2020 | 12.25 Mn |
| Sep 30, 2020 | 7.78 Mn |
| Jun 30, 2020 | 2.87 Mn |
| Mar 31, 2020 | 3.43 Mn |
| Dec 31, 2019 | 2.55 Mn |
| Sep 30, 2019 | 1.11 Mn |
| Jun 30, 2019 | 615,000.00 |
| Mar 31, 2019 | 276,000.00 |
| Dec 31, 2018 | 201,000.00 |
| Sep 30, 2018 | 240,000.00 |
| Jun 30, 2018 | 285,000.00 |
| Mar 31, 2018 | 170,000.00 |
| Dec 31, 2017 | 226,000.00 |
| Sep 30, 2017 | 278,000.00 |
| Jun 30, 2017 | 211,000.00 |
| Mar 31, 2017 | 932,000.00 |
| Dec 31, 2016 | 250,000.00 |
| Sep 30, 2016 | 243,000.00 |
| Jun 30, 2016 | 223,000.00 |
| Mar 31, 2016 | 227,000.00 |
| Dec 31, 2015 | 193,000.00 |
| Sep 30, 2015 | 189,000.00 |
| Jun 30, 2015 | 164,000.00 |
| Mar 31, 2015 | 352,000.00 |
| Dec 31, 2014 | 329,000.00 |
| Sep 30, 2014 | 54,000.00 |
| Jun 30, 2014 | 61,000.00 |
| Dec 31, 2013 | 269,000.00 |